Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT05537571

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Silence Therapeutics plc (from the registry)
Registry
  • NCT NCT05537571
Main results
  • Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial JAMA, 2024-12-17 DOI, PubMed 39556769, PMC11574722 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Czechia, Denmark, Netherlands, Slovakia, South Africa, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05537571. Randomized; double masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2024-01-11 (actual). Results posted on 2025-07-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Condition
Cardiovascular Diseases
Condition
Atherosclerosis
Condition
Lipoprotein(a)
Intervention (Drug)
SLN360
Intervention (Drug)
Placebo
Lead sponsor
Silence Therapeutics plc (class: industry)

Record details

Record id
cardio:ct-nct05537571
Content hash
a8376dc0260711e9e18c3aa3e2916e4c5e6b9831d7dc29687a0c637227c6108d